New combo therapy aims to crush T-Cell blood cancers
NCT ID NCT00501826
First seen Jun 24, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This phase II trial is testing a combination of chemotherapy drugs plus nelarabine in 160 people with previously untreated T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. The goal is to see if this stronger cocktail can improve remission rates and help people live longer without the cancer coming back. Researchers are also closely watching for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- combination chemotherapy (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, venetoclax)
- What this could lead to
- If successful, this could offer a more effective treatment option for people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma, potentially improving remission rates and long-term survival.
- What could go wrong
- This is a phase II trial, so it is still early. The combination may cause significant side effects, and it is not yet known if it will be better than standard treatments. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized chemo dosing may boost survival in kids with High-Risk leukemia
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Engineered immune cells take aim at stubborn blood cancers
- Double-Barreled immune attack aims to wipe out T-ALL
- Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
- Gene test spots hidden leukemia in kids